GleamWall
中文EN

PHIO Phio Pharmaceuticals Corp.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1533040 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-84.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-159.0%
ROA-128.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets23.8%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-19.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$4.62M$3.64M
SG&A expense$4.60M$3.74M
Operating income-$9.22M-$7.39M
Income tax$0$0
Net income-$8.70M-$7.15M
EBITDA-$9.22M-$7.38M
EPS (basic)-1.45-9.08
EPS (diluted)—-9.08
Weighted avg. shares (diluted)—787,466
Banking
Net interest income—$231,000
Balance sheet
Cash & equivalents$21.03M$5.38M
Current assets$21.48M$5.74M
PP&E, net$11,000$2,000
Total assets$21.49M$5.74M
Current liabilities—$1.01M
Total liabilities$1.34M$1.01M
Shareholders' equity$20.15M$4.72M
Shares outstanding11.62M1.73M
Cash flow statement
Operating cash flow-$7.98M-$7.11M
Capital expenditure$12,000$1,000
Free cash flow-$7.99M-$7.11M
Investing cash flow-$12,000$8,000
Financing cash flow$23.64M$4.00M
Depreciation & amortization$3,000$2,000
Stock-based compensation$481,000$147,000

Free plan shows the latest 2 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.